Clear Benefit With Adjuvant Nivolumab in Resected Melanoma

Adjuvant nivolumab significant improves relapse-free survival and reduces toxicity in comparison with ipilimumab in stage III/IV resected melanoma for patients at risk for relapse, trial results reveal.
Medscape Medical News

http://ift.tt/2xuwFXF